Citation Tools
PDFRegular and young investigator award abstracts
Clinical trials in progress
359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results